SLC5A8 nuclear translocation and loss of expression are associated with poor outcome in pancreatic ductal adenocarcinoma

Pancreas

Volumn 41, Issue 6, 2012, Pages 904-909

  Helm, James ^a   Coppola, Domenico ^a   Ganapathy, Vadivel ^b   Lloyd, Mark ^a   Centeno, Barbara A ^a   Chen, Dung Tsa ^a   Malafa, Mokenge P ^a   Park, Jong Y ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

pancreatic cancer; SLC5A8; survival; tissue microarray; tumor suppressor gene

Indexed keywords

SODIUM CHANNEL; SODIUM CHANNEL SLC5A8; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PANCREAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ACTIVE TRANSPORT, CELL NUCLEUS; ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; CATION TRANSPORT PROTEINS; CELL NUCLEUS; DOWN-REGULATION; FEMALE; FLORIDA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84863958857     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31823f429f     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CACancer J Clin. 2010;60:277Y300.
2. Ganapathy V, Thangaraju M, Gopal E, et al. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10:193Y199.
3. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2009;121:29Y40.
4. Gopal E, Miyauchi S, Martin PM, et al. Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract. Pharm Res. 2007;24:575Y584.
5. Martin PM, Gopal E, Ananth S, et al. Identity of SMCT1 (SLC5A8) as a neuron-specific Na+-coupled transporter for active uptake of L-lactate and ketone bodies in the brain. J Neurochem. 2006;98:279Y288.
6. Gupta N, Martin PM, Prasad PD, et al. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci. 2006;78:2419Y2425.
7. Thangaraju M, Gopal E, Martin PM, et al. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res. 2006;66:11560Y11564.
8. Li H, Myeroff L, Smiraglia D, et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A. 2003;100:8412Y8417.
9. Hong C, Maunakea A, Jun P, et al. Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8. Cancer Res. 2005;65:3617Y3623.
10. Dong SM, Lee EJ, Jeon ES, et al. Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Pathol. 2005;18:170Y178.
11. Paroder V, Spencer SR, Paroder M, et al. Na(+)/monocarboxylate transport (SMCT) protein expression correlates with survival in coloncancer: molecular characterization of SMCT. Proc Natl Acad Sci U S A. 2006;103:7270Y7275.
12. Thangaraju M, Cresci G, Itagaki S, et al. Sodium-coupled transport of the short chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer. J Gastrointest Surg. 2008;12:1773Y1781; discussion 1781Y1782.
13. Porra V, Ferraro-Peyret C, Durand C, et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab. 2005;90:3028Y3035.
14. Hu S, Liu D, Tufano RP, et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer. 2006;119:2322Y2329.
15. Schagdarsurengin U, Gimm O, Dralle H, et al. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid. 2006;16:633Y642.
16. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology. 2007;148:948Y953.
17. Ueno M, Toyota M, Akino K, et al. Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol. 2004;25:134Y140.
18. Park J, Brena RM, Gruidl M, et al. CpG island hypermethylation profiling of lung cancer using restriction landmark genomic scanning (RLGS) analysis. Cancer Biomark. 2005;1:193Y200.
19. Park JY, Zheng W, Kim D, et al. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev. 2007;31:359Y365.
20. Bennett KL, Karpenko M, Lin MT, et al. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res. 2008;68:4494Y4499.
21. Whitman SP, Hackanson B, Liyanarachchi S, et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood. 2008;112:2013Y2016.
22. Park JY, Helm JF, Zheng W, et al. Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas. 2008;36:e32Ye39.
23. Helm JF, Centeno BA, Coppola D, et al. Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control. 2008;15:288Y294.
24. Helm J, Centeno BA, Coppola D, et al. Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer. Cancer. 2009;115:4080Y4089.
25. Wong SC, Lo ES, Lee KC, et al. Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res. 2004;10:1401Y1408.
26. Li XH, Kikuchi K, Zheng Y, et al. Downregulation and translocation of nuclear ING4 is correlated with tumorigenesis and progression of head and neck squamous cell carcinoma. Oral Oncol. 2011;47:217Y223.
27. Aytekin T, Ozaslan M, Cengiz B. Deletion mapping of chromosome region 12q13-24 in colorectal cancer. Cancer Genet Cytogenet. 2010;201:32Y38.
28. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350Y353.
29. Kloth JN, Kenter GG, Spijker HS, et al. Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival. Mod Pathol. 2008;21:866Y875.
30. Maass N, Hojo T, Ueding M, et al. Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res. 2001;7:812Y817.
31. Oh YL, Song SY, Ahn G. Expression of maspin in pancreatic neoplasms: application of maspin immunohistochemistry to the differential diagnosis. Appl Immunohistochem Mol Morphol. 2002;10:62Y66.
32. Cao D, Zhang Q, Wu LS, et al. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod Pathol. 2007;20:570Y578.
33. Ganapathy V, Gopal E, Miyauchi S, et al. Biological functions of SLC5A8, a candidate tumour suppressor. Biochem Soc Trans. 2005;33:237Y240.
34. Thangaraju M, Karunakaran SK, Itagaki S, et al. Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. Cancer. 2009;115:4655Y4666.
35. Zhang Y, Bao YL, Wu Y, et al. Identification and characterization of the human SLC5A8 gene promoter. Cancer Genet Cytogenet. 2010;196:124Y132.
36. Zhang Y, Bao YL, Yang MT, et al. Activin A induces SLC5A8 expression through the Smad3 signaling pathway in human colon cancer RKO cells. Int J Biochem Cell Biol. 2010;42:1964Y1972.